



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hunter et al.

Application No. 10/716,379 Filed: November 17, 2003 Confirmation No. 4384

For: NIMA INTERACTING PROTEINS

Examiner: Lei Yao, Ph.D.

Art Unit: 1642

Attorney Reference No. 7158-71253-12

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: nema sudm

Date Mailed September 28, 2005

## TRANSMITTAL LETTER

Enclosed for filing in the above-referenced application are the following (collectively, an "IDS"):

☐ Information Disclosure Statement;

Form 1449, and

 $\overline{\boxtimes}$  Copies of references (48).

The Director is hereby authorized to charge any fees that may be required to file this IDS to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Debra A. Gordon, Ph.D.

Registration No. 54,128

cc: Docketing

# SEP 3 0 2005

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Hunter et al.

Application No. 10/716,379 Filed: November 17, 2003 Confirmation No. 4384

For: NIMA INTERACTING PROTEINS

Examiner: Lei Yao, Ph.D.

Art Unit: 1642

Attorney Reference No. 7158-71253-12

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: nehrandm

Date Mailed September 28, 2005

# INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

The above-referenced application relies upon U.S. Patent Application No. 10/616,410, filed July 8, 2003; U.S. Patent Application No. 09/275,900, filed March 24, 1999, now issued as U.S. Patent No. 6,596,848; U.S. Patent Application No. 09/066,074, filed April 24, 1998, now issued as U.S. Patent No. 5,952,467; and U.S. Patent Application No. 08/555,912, filed November 13, 1995, now issued as U.S. Patent No. 5,972,697 (collectively, "Priority Applications"), for an earlier filing date under 35 U.S.C. §120.

Listed on the accompanying form PTO-1449 are several English-language documents, some of which were disclosed to, or cited by, the United States Patent and Trademark Office ("Patent Office") in the Priority Applications. Applicants respectfully request that each document listed on the form PTO-1449 be shown as a reference cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. §1.98(a)(2)(ii)). Copies of unpublished U.S. patent applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. §1.98(a)(2)(iii) has been waived by the Patent Office (1287 OG 163). Copies of the documents listed on the accompanying form PTO-1449 that were submitted by Applicants or cited by the Patent Office in one of the Priority Applications need not

be sent to the Patent Office (37 C.F.R. §1.98). Applicants will provide copies of any of such patents, applications, or documents upon request.

This Information Disclosure Statement ("IDS") is filed before the mailing date of a first Office action on the merits; therefore, no filing fee should be required (37 C.F.R. 1.97(b)(3)). However, if the Patent Office determines that a fee is required to file this IDS, please charge such fee to the deposit account referenced on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Debra A. Gordon, Ph.D.

Registration No. 54,128

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

SEP 3 0 2005

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	7158-71253-12
Application Number	10/716,379
Filing Date	November 17, 2003
First Named Inventor	Hunter
Art Unit	1642
Examiner Name	Lei Yao, Ph.D.

# **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,443,962	08/22/1995	Draetta et al.
		5,952,467	09/14/1999	Hunter et al.
		6,596,848	07/22/2003	Hunter et al.
		2002/0025521	02/28/2002	Lu et al.
		2003/0225528	12/04/2003	Baker et al.
		2004/0101896	05/27/2004	Hunter et al.
		2004/0171019	09/02/2004	Matthews et al.
		2005/0027107	02/03/2005	Hunter et al.
		2005/0049404	03/03/2005	Hunter et al.

## FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	<b>Publication Date</b>	Name of Applicant or Patentee
		WIPO	WO 99/12962	03/1999	Lu et al.
		WIPO	WO 00/48621	08/2000	Lu et al.
		WIPO	WO 01/75067	10/2001	Drmanac et al.
		WIPO	WO 01/79449	10/2001	Tang et al.

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	7158-71253-12
Application Number	10/716,379
Filing Date	November 17, 2003
First Named Inventor	Hunter
Art Unit	1642
Examiner Name	Lei Yao, Ph.D.

			Examiner Name	Lei Yao, Ph.D.		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
•		#1230, Random Primer, New England Biolabs, Catalog 1993/4.				
-		Amon et al., "Regulation of p34 <sup>CDC2</sup> into mitosis in S. cerevisiae." Natur		s not required for entry		
		Burgess et al., "Possible dissociation		mitogenic activities of		
		heparin-binding (acidic fibroblast) g	rowth factor-1 from its recep	otor-binding activities by		
		site-directed mutagenesis of a single	lysine residue." J. Cell Biod	<i>l.</i> , 111:2129-2138, 1990.		
		Cech, "Ribozymes and Their Medica 3034, 1988.	Cech, "Ribozymes and Their Medical Implications." J. Am. Med. Assn., 260(20):3030-			
		Choi et al., "Activation of p34 <sup>cdc2</sup> protein kinase activity in meiotic and mitotic cell cycles in mouse oocytes and embryos." <i>Development</i> , 113:789-795, 1991.  Chong et al., "A human telomeric protein." <i>Science</i> , 270:1663-1667, 1995.				
. 1		Durfee et al., "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit." Genes Dev., 7:555-569, 1993.				
		Dyck et al., "A Novel Macromolecular Structure Is a Target of the Promyelocyte-Retinoid Acid Receptor Oncoprotein." Cell, 76:333-343, 1994.				
		Eldredge et al., "Use of Tetracycline Operator System to Regulate Oncogene Expression in Mammalian Cells." <i>Methods Enzymol.</i> , 254:481-491, 1995.		te Oncogene Expression		
		Engleman, Human Hydbridomas and Monoclonal Antibodies, New York:Plenum Press, 1985.				
		Fields and Song, "A novel genetic system to detect protein-protein interactions." <i>Nature</i> , 340:245-246, 1989.  Fraley and Papahadjopoulos, "New generation lipsomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids." <i>Trends Biochem. Sci.</i> , 6:77-80, 1981.  Fruman <i>et al.</i> , "Immunophilins in protein folding and immunosuppression." <i>FASEB J.</i> , 8:391-400, 1994.				
	Fu and Maniatis, "Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus." <i>Nature</i> , 343:437-441, 1990.			-		
		Fujimori et al., "Mice Lacking Pin1 Cell Cycle from G <sub>0</sub> Arrest." Biochem				
		Gavin et al., "Histone H1 kinase acti in mouse oocytes." J. Cell Sci., 107:	• • •	down and M phase entry		

EXAMINER DATE SIGNATURE: CONSIDERED:	
--------------------------------------	--

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	7158-71253-12
		Application Number	10/716,379
INFORMATION DISCLOSURE STATEMENT		Filing Date	November 17, 2003
	BY APPLICANT	First Named Inventor	Hunter
		Art Unit	1642
		Examiner Name	Lei Yao, Ph.D.
	Gossen and Bujard, "Tight control or responsive promoters." <i>Proc. Natl.</i> 2		
	Gui et al., "A serine kinase regulates cell cycle." Nature, 369:678-682, 19	intracellular localization of	
	Hanes et al., "Sequence and Mutatio Saccharomyces cerevisiae." Yeast, S		e Essential for Growth in
	Hani et al., "PTF1 encodes an essent	tial protein in Saccharomyce	
	shows strong homology with a new putative family of PPIases." <i>FEBS Lett.</i> , 365:198-202, 1995.		
	Hannon et al., "Isolation of the Rb-related p130 through its interaction with CDK2 and		
	cyclins." Genes Dev., 7:2378-2391, 1993.		
	Harper et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-		
	Dependent Kinases." <i>Cell</i> , 75:805-816, 1993.  Heitman <i>et al.</i> , "Identification of Immunosuppressive Drug Targets in Yeast." <i>Methods</i> .		
-	Companion Methods Enzymol., 5:176-187, 1993.		
	Helene, "The anti-gene strategy: control of gene expression by triplex-forming-		
	oligonucleotides." Anticancer Drug Des., 6:569-584, 1991 (abstract only).		
	Hillier et al., EST-STS Database, Accession No. H41102, 1991.		
	Hillier et al., EST-STS Database, Accession No. T82035, 1995.		
	Jaye <i>et al.</i> , "Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovin		
	factor IX." Nucl. Acid Res., 11(8):2325-2335, 1983.		
	Jung et al., "Kinetics of MPF and histone H1 kinase activity differ during the G2- to		
	M-phase transition in mouse oocytes		
	Kohler and Milstein, "Continuous cu specificity." <i>Nature</i> , 256:495-497, 1	975.	
	Lambert-Messerlian et al., "Human f	• • • • • • • • • • • • • • • • • • •	
	immunoreactive alpha-inhibin precui 78:433-439, 1994.	rsor proteins." J. Clin. Endo	crinol. Metab.,
	Lazar <i>et al.</i> , "Transforming growth fa 48 results in different biological activ		
	Lee and Nathans, "Proliferin Secrete Receptors." J. Biol. Chem., 263(7):3	d by Cultured Cells Binds to	

EXAMINER DATE CONSIDERED:	
---------------------------	--

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Attorney Docket Number	7158-71253-12	
	Application Number	10/716,379	
INFORMATION DISCLOSURE STATEMENT	Filing Date	November 17, 2003	
BY APPLICANT	First Named Inventor	Hunter	
	Art Unit	1642	
	Examiner Name	Lei Yao, Ph.D.	
Lu et al., "Properties and regulation Aspergillus nidulans." J. Biol. Chen		MA protein kinase of	
Lu et al., "Identification of Substrate			
regulated NIMA Protein Kinase." J			
Lu <i>et al.</i> , "Evidence for a NIMA-lik 81:413-424, 1995.			
Lu <i>et al.</i> , "Expression of the noncata in Aspergillus nidulans." <i>EMBO J.</i> ,	-	inase causes a G2 arrest	
Lu et al., "A human peptidyl-prolyl Nature, 380:544-547, 1996	isomerase essential for regula	ation of mitosis."	
	Maher et al., "Oligonucleotide-Directed DNA Triple-Helix Formation: An Approach to Artificial Repressors?" Antisense Res. Dev., 1:277-281, 1991.		
	Mannino and Gould-Fogerite, "Liposome Mediated Gene Transfer." Biotechniques,		
	Marcus-Sekura, "Review: Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression." <i>Anal. Biochem.</i> , 172:289-295, 1988.		
	Morris et al., "The genetic analysis of mitosis in Aspergillus nidulans." Bioessays,		
O'Connell <i>et al.</i> , "Premature chroma <i>EMBO J.</i> , 13:4926-4937, 1994.	O'Connell et al., "Premature chromatin condensation upon accumulation of NIMA."		
Osmani <i>et al.</i> , "Mitotic induction and maintenance by overexpression of a G2-specific gene that encodes a potential protein kinase." <i>Cell</i> , 53:237-244, 1988.			
Osmani <i>et al.</i> , "Parallel Activation of the NIMA and p34 <sup>cdc2</sup> Cell Cycle-Regulated Protein Kinases Is Required to Initiate Mitosis in A. nidulans." <i>Cell</i> , 67:283-291, 1991.		Cycle-Regulated Protein	
Peattie et al., "Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes." <i>Proc. Natl. Acad. Sci. USA</i> , 89:10974-10979, 1992.		2, an immunophilin that t of steroid receptor	
cis/trans isomerases: Amino acid se <i>FEBS Lett.</i> , 352:180-184, 1994.	Rahfeld <i>et al.</i> , "Confirmation of the existence of a third family among peptidyl-prolyl cis/trans isomerases: Amino acid sequence and recombinant production of parvulin."		
Rosborough et al., "Identification of predetermined specificity and isolati Transplantation Proc., 23:2890-289	on by FK 506 affinity chrom		
Rosenberg et al., "Vectors for selective expression of cloned DNAs by T7 RNA polymerase." Gene, 56:125-135, 1987.			

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE:	CONSIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Attorney Docket Number	7158-71253-12	
	Application Number	10/716,379	
INFORMATION DISCLOSURE STATEMENT	Filing Date	November 17, 2003	
BY APPLICANT	First Named Inventor	Hunter	
	Art Unit	1642	
	Examiner Name	Lei Yao, Ph.D.	
Rudd <i>et al.</i> , "A new family of per 20:12-14, 1995.			
Sazer <i>et al.</i> , "Mitochondrial growth and DNA synthesis occur in the absence of nuclear DNA replication in fission yeast." <i>J. Cell Sci.</i> , 97:509-516, 1990.			
Schreiber, "Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands." Science, 251:283-287, 1991.			
Schultz et al., "Cell Cycle-dependent Expression of Nek2, a Novel Human Protein Kinase			
Related to the NIMA Mitotic Regulator of Asperigillus nidulans <sup>1</sup> ." Cell. Growth Differ., 5:625-635, 1994.			
	Schultz et al., "Identification of 21 Novel Human Protein Kinases, Including 3 Members		
· · · · · · · · · · · · · · · · · · ·	of a Family Related to the Cell Cycle Regulator nimA of Aspergillus nidulans <sup>1</sup> ." Cell		
Growth Differ., 4:821-830, 1993.	ecential protein kinace gene in S	Jacobaromyoos caravisiaa	
	Schweitzer et al., "NPK1, a nonessential protein kinase gene in Saccharomyces cerevisiae with similarity to Aspergillus nidulans nimA." Mol. Gen. Genet., 234:164-167, 1992.		
Sikorski and Hieter, "A System o			
1 ·	Efficient Manipulation of DNA in Saccharomyces cerevisiae." Genetics, 122:19-27,		
	1989.		
phosphorylation of p34 <sup>cdc28</sup> ." Na.	Sorger and Murray, "S-phase feedback control in budding yeast independent of tyrosine phosphorylation of p34 <sup>cdc28</sup> ." <i>Nature</i> , 355:365-368, 1992.		
Stueland et al., "Full Activiation	Stueland et al., "Full Activiation of p34 Histone H1 Kinase Activity Is Unable To		
	Promote Entry into Mitosis in checkpoint-Arrested Cells of the Yeast Saccharomyces cerevisiae." Mol. Cell. Bio., 13:3744-3755, 1993.		
Sudol et al., "Characterization of a novel protein-binding module – the WW domain."  FEBS Lett., 369:67-71, 1995.			
Sudol et al., "Characterization of the Mammalian YAP (Yes-associated Protein) Gene and			
Its Role in Defining a Novel Prote 270(24):14733-14741, 1995.	Its Role in Defining a Novel Protein Module, the WW Domain." J. Biol. Chem.,		
Wallace et al., "The use of synthetic oligonucleotides as hybridization probes. II.			
Hybridization of oligonucleotides  Acid Res., 9(4):879-894, 1981.	Hybridization of oligonucleotides of mixed sequence to rabbit β-globin DNA." <i>Nucl. Acid Res.</i> , 9(4):879-894, 1981.		
Weintraub, "Antisence RNA and	DNA." Scientific American, 26	52:40-46, 1990.	
Yocum et al., "Use of lacZ fusions to Delimit Regulatory Elements of the Inducible Divergent GAL1-GAL10 Promoter in Saccharomyces cerevisiae." Mol. Cell. Bio., 4(10):1985-1998, 1984.			

EXAMINER DATE CONSIDERED:
---------------------------

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	7158-71253-12
	Application Number	10/716,379
	Filing Date	November 17, 2003
	First Named Inventor	Hunter
	Art Unit	1642
	Examiner Name	Lei Yao, Ph.D.
Yoon et al., "Genetic and Biochemical Interactions between an Essential Kinetochore Protein, Cbf2p/Ndc10p, and the CDC34 Ubiquitin-Conjugating Enzyme." Mol. Cell. Biol., 15:4835-4842, 1995		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.